WO2001032663A2 - Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant - Google Patents
Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant Download PDFInfo
- Publication number
- WO2001032663A2 WO2001032663A2 PCT/FR2000/003049 FR0003049W WO0132663A2 WO 2001032663 A2 WO2001032663 A2 WO 2001032663A2 FR 0003049 W FR0003049 W FR 0003049W WO 0132663 A2 WO0132663 A2 WO 0132663A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- alkyl
- compound according
- acid
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Definitions
- the subject of the present invention is compounds which are antagonists of the CB ⁇ cannabinoid receptors, their preparation and pharmaceutical compositions containing them.
- the compounds of the invention are tricyclic derivatives of pyrazolecarboxylic acid.
- Patent applications EP-A-576,357, EP-A-658,546 and WO-97/19063 describe derivatives of pyrazole having an affinity for cannabinoid receptors.
- patent application EP-A-656 354 claims N-piperidino-5- (4-chlorophenyl) -l- (2,4-dichlorophenyl) -4-methylpyrazole-3-carboxamide and its pharmaceutically acceptable salts which have a very good affinity for CB] ⁇ cannabinoid receptors.
- International patent application WO-96/09304 describes compounds inhibiting cyclooxygenase, more specifically cyclooxygenase-2. These compounds useful in the treatment of inflammation and inflammatory diseases correspond to the formula:
- A, B, R a , Rfc, R ⁇ j have different meanings.
- ⁇ ⁇ -THC is the main active ingredient extracted from Cannabis sativa (Tuner, 1985; In Marijuana 84, Ed. Harvey, DY, IRL Press, Oxford).
- cannabinoids due to an interaction with specific high affinity receptors present at the central (Devane et al., Mol. Pharmacol., 1988, 34, 605-613) and peripheral (Nye et al., Pharmacol. And
- - XY- represents a group chosen from - (CH2) n -CH2-, -CH2-S (O) -, or -S (O) p -CH 2 -;
- - n is equal to 1 or 2;
- - p is zero, 1 or 2;
- S2>S3> ⁇ 4 'S5> w 2> w 3' w 4 '5' w 6 are the same or different and each independently represents hydrogen, a halogen, a trifluoromethyl, a (C ⁇ -C4) alkyl, a (C ⁇ -C4) alkoxy, a (C ⁇ -C4) alkylthio, a nitro; at least one of the substituents w, W3, W4, W5, W6 being different from hydrogen;
- - R represents a non-aromatic C3-C15 carbocyclic radical which is unsubstituted or substituted one or more times with a (Cj-C4) alkyl, or a group NR2R3;
- R and R3 each independently represent hydrogen or a (C ⁇ -C6) alkyl, or R 2 and R3 together with the nitrogen atom to which they are linked constitute a saturated or unsaturated 5 to 10-membered heterocyclic radical, not substituted or substituted one or more times by a (C ⁇ -C4) alkyl; as well as their salts and their solvates.
- alkyl is meant straight or branched alkyl.
- the methyl, ethyl, propyl, isopropyl groups being preferred.
- saturated or unsaturated 5 to 10-membered heterocyclic radical is intended to mean a non-aromatic mono or dicyclic, condensed or bridged heterocyclic radical, which may comprise a second heteroaroma.
- radicals include in particular the following radicals: 1-pyrrolidinyl, 1-piperidinyl, 1- hexahydroazepinyl, 4-morpholinyl, 8-azaspiro [4.5] dec-8-yle, bicyclo [2.2.1] heptan-2-yle.
- non-aromatic C3-C15 carbocyclic radical is meant a saturated, mono or polycyclic, condensed, bridged or spiranic radical; a saturated, condensed or bridged radical being preferred.
- These radicals include in particular the following radicals: cyclopentyl, cyclohexyl or adamantyl or fenchyl.
- Halogen means a chlorine, bromine, fluorine or iodine atom.
- the optional salts of the compounds of formula (I) include the pharmaceutically acceptable acid addition salts such as the hydrochloride, the hydrobromide, the sulfate, the hydrogen sulfate, the dihydrogen phosphate, the methanesulfonate, the methyl sulfate, the maleate, oxalate, fumarate, naphthalenesulfonate, glyconate, gluconate, citrate, isethionate, paratoluenesulfonate, methylenesulfonate, benzenesulfonate or succinate.
- the pharmaceutically acceptable acid addition salts such as the hydrochloride, the hydrobromide, the sulfate, the hydrogen sulfate, the dihydrogen phosphate, the methanesulfonate, the methyl sulfate, the maleate, oxalate, fumarate, naphthalenesulfonate, glyconate, glucon
- the present invention relates particularly to compounds of formula:
- - XY- represents a group chosen from - (CH2) n -CH2-, -CH2-S (O) -, or -S (O) p -CH 2 -;
- - n is equal to 1 or 2;
- - p is zero, 1 or 2;
- w 2> w 3 ' w 4> w 5> w 6 are the same or different and each independently represents hydrogen, a halogen, a trifluoromethyl, a (C ⁇ -C3) alkyl, a (C ⁇ -C3) alkoxy, a (Ci -C3) alkylfhio, a nitro; at least one of the substituents W2, W3, W4, W5, wg being different from hydrogen;
- - R represents a non-aromatic C3-C15 carbocyclic radical unsubstituted or substituted one or more times by a (C ⁇ -C4) alkyl, or a group NR2R3;
- R2 and R3 each independently represent hydrogen or a (C ⁇ -C6) alkyl, or R2 and R3 together with the nitrogen atom to which they are attached constitute a radical saturated or unsaturated 5 to 10 membered heterocyclic, unsubstituted or substituted one or more times with a (C ⁇ -C4) alkyl; as well as their salts and their solvates.
- the compounds of formula (I) preferred are those in which g2, g3, g5, W3, 5 > 6 represent hydrogen and g4, 2 and W4 have one of the values defined above for the compounds of formula (I), except hydrogen. More particularly, the compounds of formula (I) are preferred in which W2 and W4 represent chlorine and g4 represents chlorine or bromine.
- R1 represents a non-aromatic C3-C15 carbocyclic radical which is unsubstituted or substituted one or more times by a (Cj-C4) alkyl.
- R represents NR2R3, R2 and R3 constituting with the nitrogen atom to which they are linked a heterocyclic radical saturated with 5 to 10 members, unsubstituted or substituted one or more times with a (C ⁇ -C4) alkyl.
- LiHMDS lithium salt of hexamethyldisilazane (CO j Et: ethyl oxalate APTS: paratoluenesulfonic acid
- PPA polyphosphoric acid
- the present invention also relates to a process for preparing a compound according to the invention, its salts and its solvates. This process is characterized in that a functional derivative of an acid of formula:
- reaction is carried out in basic medium, for example in the presence of triethylamine in a solvent such as dichloromefhane or tetrahydrofuran.
- an activated ester for example, can be used as functional derivative of acid (H), acid chloride, anhydride, a mixed anhydride, a C1-C4 alkyl ester in which the alkyl is straight or branched.
- an activated ester for example, can be used.
- p-nitrophenyl ester, or free acid suitably activated, for example, with N, N-dicyclohexylcarbodiimide or with benzotriazol hexafluorophosphate-N-oxotris (dimethylamino) phosphonium (BOP).
- the acid chloride of formula (H) obtained by reaction of thionyl chloride with the acid of formula (II) can be reacted in an inert solvent such as benzene or toluene or a chlorinated solvent (dichloromethane, dichloroethane, chloroform for example), an ether
- An alternative to the procedure consists in preparing the mixed anhydride of the acid of formula (H) by reaction of ethyl chloroformate with the acid of formula (H), in the presence of a base such as triethylamine.
- the starting acids (II) are new and constitute another aspect of the present invention, their functional derivatives are also new, in particular their acid chlorides and their C1-C4 alkyl esters.
- W5 represents a fluorine or a trifluoromethyl, g2, g3, g4, g5, w 2 , W3, W4, W5, wg do not simultaneously represent l 'hydrogen;
- W4 represents chlorine and g4 represents hydrogen or methoxy, g 2 , g3, g5, w 2 , W3, W5, wg do not simultaneously represent hydrogen.
- 7-chloroisothiochroman-4-one, 7-fluoroisothio chroman-4-one as well that 7-chlorothiochroman-4-one are described in this international application WO-96/09304.
- a compound of formula (VIII) is prepared in which -XY- represents respectively -CH2-S- or respectively -S-CH2 and an oxidizing agent such as metachloroperbenzoic acid is made to act, either in equimolar amount to obtain a sulfoxide, or in double amount to obtain a sulfone.
- the benzosuberones of formula (TV) in which -X-Y- represents - (CH2) 2- CH2- are known or prepared according to J. Med. Chem., 1991, 37, 3482-3491 and J. Org. Chem., 1962, 27, 7076.
- the lithium salt of formula (V) is prepared by the action of a lithiated base such as hexamethyldisilazane and then ethyl oxalate.
- the compound of formula (I) obtained by the process according to the invention is isolated, in the form of the free base or of the salt or of the solvate, according to conventional techniques.
- the compound of formula (I) can be isolated in the form of one of its salts, for example the hydrochloride or the oxalate; in this case, the free base can be prepared by neutralizing said salt with an inorganic or organic base, such as sodium or ammonium hydroxide, triethylamine or an alkali carbonate or bicarbonate such as sodium carbonate or bicarbonate or potassium, and transformed into another salt such as methanesulfonate, fumarate or 2-naphthalenesulfonate.
- an inorganic or organic base such as sodium or ammonium hydroxide, triethylamine or an alkali carbonate or bicarbonate such as sodium carbonate or bicarbonate or potassium
- another salt such as methanesulfonate, fumarate or 2-naphthalenesulfonate.
- the compounds of formula (I) have a very good in vitro affinity for the cannabinoid receptors CBi, under the experimental conditions described by Devane et al., Mol. Pharmacol., 1988, 34. 605-613.
- the compounds of the present invention are potent and selective antagonists of the cannabinoid receptors CBi, having a Ki lower than
- the toxicity of the compounds (I) is compatible with their use as a medicament.
- the present invention relates to the use of the compounds of formula (I), or of one of their pharmaceutically acceptable salts and solvates, for the preparation of medicaments intended for treating diseases involving the cannabinoid receptors OB ⁇ .
- the compounds of formula (I) are useful as psychotropic drugs, in particular for the treatment of anxiety disorders, mood disorders, delusional disorders, psychotic disorders in general, for the treatment of schizophrenia, depression, as well as for the treatment of disorders linked to the use of psychotropic substances, in particular in the case of substance abuse and / or dependence on a substance, including alcohol dependence.
- the compounds (I) according to the invention can be used as medicaments for the treatment of neuropathies, migraine, stress, diseases of psychosomatic origin, epilepsy, movement disorders, in particular dyskinesias or Parkinson's disease.
- the compounds (I) according to the invention can also be used as medicaments in the treatment of memory disorders, cognitive disorders, in particular in the treatment of senile dementias, of Alzheimer's disease, as well as in the treatment of attention or alertness disorders and as a neuroprotective.
- the compounds (I) according to the invention can be used as medicaments in appetite, appetite disorders (for sugars, carbohydrates, drugs, alcohols or any appetizing substance) and / or food conducts, in particular in as an appetite suppressant or for the treatment of obesity or bulimia as well as for the treatment of type II diabetes or non-insulin dependent diabetes and in smoking cessation.
- the compounds of formula (I) according to the invention can be used as medicaments in gastrointestinal disorders, vomiting, bladder and urinary disorders, cardiovascular disorders, fertility disorders, inflammatory phenomena, infectious diseases as well as as drugs for cancer chemotherapy.
- the compounds according to the present invention can also be useful in the treatment of neuroinflammatory pathologies, in particular the diseases causing demyelization such as multiple sclerosis or Guillain-Barré syndrome, as well as viral encephalitis, cerebrovascular accidents, head trauma, for example.
- the compounds of formula (I) are very particularly useful for the treatment of psychotic disorders, in particular schizophrenia; for the treatment of appetite disorders and obesity, for smoking cessation and for the treatment of memory and cognitive disorders.
- the present invention relates to the use of a compound of formula (I) for the treatment of the disorders and diseases indicated above.
- the present invention also relates to the use of the compounds of formula (I), as such or in radiolabelled form as pharmacological tools in humans or in animals, for the detection and labeling of receptors CB ⁇ .
- the compounds according to the invention are generally administered in dosage units.
- Said dosage units are preferably formulated in pharmaceutical compositions in which the active principle is mixed with a pharmaceutical excipient.
- the present invention relates to pharmaceutical compositions containing, as active principle, a compound of formula (I), one of its pharmaceutically acceptable salts or one of their solvates.
- the compounds of formula (I) above and their pharmaceutically acceptable salts or solvates can be used in daily doses of 0.01 at 100 mg per kg of body weight of the mammal to be treated, preferably at daily doses of 0.1 to 50 mg kg.
- the dose may preferably vary from 0.5 to 4000 mg per day, more particularly from 2 to 1000 mg per day depending on the age of the subject to be treated or the type of treatment, namely prophylactic or curative .
- the active principle can be administered in unit administration form, in admixture with carriers conventional pharmaceuticals, animals and humans.
- Suitable unit administration forms include oral forms such as tablets, capsules, powders, granules and oral solutions or suspensions, sublingual and oral administration forms, aerosols, administration forms topical, implants, forms of subcutaneous, intramuscular, intravenous, intranasal or intraocular administration and forms of rectal administration.
- the active ingredient is generally formulated in dosage units containing from 0.1 to 1000 mg, advantageously from 0.5 to 500 mg, preferably from 1 to 200 mg of said active ingredient per unit of dosage for daily administrations.
- a wetting agent such as sodium lauryl sulphate can be added to the active principle, micronized or not, and the whole is mixed with a pharmaceutical vehicle such as silica, gelatin, starch, lactose, magnesium stearate, talc, gum arabic or the like.
- a pharmaceutical vehicle such as silica, gelatin, starch, lactose, magnesium stearate, talc, gum arabic or the like.
- the tablets can be coated with sucrose, various polymers or other suitable materials or else they can be treated in such a way that they have a prolonged or delayed activity and that they continuously release a predetermined quantity of active principle.
- a preparation in capsules is obtained by mixing the active principle with a diluent such as a glycol or a glycerol ester and by incorporating the mixture obtained in soft or hard capsules.
- a preparation in the form of a syrup or elixir may contain the active principle together with a sweetener, preferably calorie-free, methylparaben and propylparaben as antiseptics, as well as a flavoring agent and an appropriate color.
- the powders or granules dispersible in water can contain the active principle in mixture with dispersing agents, wetting agents, or agents suspension, such as polyvinylpyrrolidone, as well as with sweeteners or flavor correctors.
- Suppositories are used for rectal administration which are prepared with binders that melt at rectal temperature, for example cocoa butter or polyethylene glycols.
- aqueous suspensions, isotonic saline solutions or sterile and injectable solutions which contain pharmacologically compatible dispersing agents and / or solubilizing agents, for example propylene glycol or polyethylene glycol.
- a cosolvent such as for example an alcohol such as ethanol or a glycol such as polyethylene glycol or propylene glycol, and a hydrophilic surfactant such as Tween® 80.
- the active principle can be dissolved by a triglyceride or a glycerol ester.
- creams, ointments or gels can be used.
- patches may be used in multilaminate form or in reservoirs in which the active principle may be in alcoholic solution.
- an aerosol containing, for example, sorbitan trioleate or oleic acid, as well as trichlorofluoromethane, dichlorofluoromethane, dichlorotetrafluoroethane or any other biologically compatible propellant is used; one can also use a system containing the active ingredient alone or associated with an excipient, in the form of powder.
- the active principle can also be formulated in the form of microcapsules or microspheres, optionally with one or more carriers or additives.
- the active principle can also be presented in the form of a complex with a cyclodextrin, for example ⁇ -, ⁇ - or ⁇ -cyclodextrin, 2-hydroxypropyl- ⁇ - cyclodextrin or methyl- ⁇ -cyclodextrin.
- implants can be used. These can be prepared in the form of an oily suspension or in the form of a suspension of microspheres in an isotonic medium. PREPARATION 1
- This compound is prepared according to the procedure described in international patent application WO 96/09304.
- the reaction mixture is poured into 500 ml of ice water, the precipitate formed is drained, washed with water and dried under vacuum. 1.93 g of the expected product are obtained,
- a solution of 0.86 g of metachloroperbenzoic acid in 100 ml of DCM is prepared, then it is added dropwise to a solution at 0 ° C containing 1.47 g of ester obtained in PREPARA ⁇ ON 1, step D in solution in 100 ml of DCM.
- 50 ml of 5% Na2CO3 solution are added and the mixture is then stirred for 15 minutes. It is extracted with DCM and then washed with a saturated solution and then a dilute NaCl solution. After evaporation of the solvents and drying, the residue is chromatographed on silica, eluting with a toluene / AcOEt mixture (90/10; v / v). 0.99 g of the expected compound are obtained.
- Benzosuberone (6,7,8,9-tetrahydrobenzocyclohepten-5-one) is commercial.
- PREPARATION 7 8-Chloro- 1 - (2,4-dichlorophenyl) - 1, 4,5, 6-tetrahydro- 1,2,2-diazabenzo [e] azulene-3-carboxylic acid.
- the solution obtained in the previous step is cooled to between 0 ° C and 5 ° C and a solution of 1.02 g of sodium nitrite in 5 ml of water is added dropwise, followed by stirring for 15 minutes.
- a solution of 0.2 ml of 1-aminopiperidine and 0.25 ml of triethylamine in 15 ml of DCM is cooled to 0 ° C., a solution of 0.73 g of the compound obtained in the preceding step is added dropwise 15 ml of DCM and left stirring for 18 hours at RT.
- the reaction mixture is poured into 200 ml of water, extracted with DCM, the organic phase is washed with water, with a saturated NaCl solution, dried over Na 2 S ⁇ 4 and the solvent is evaporated under vacuum.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001535365A JP4964380B2 (ja) | 1999-11-03 | 2000-11-02 | ピラゾールカルボン酸の三環式誘導体、その製造法およびそれを含む医薬組成物 |
EP00974629A EP1230244B1 (fr) | 1999-11-03 | 2000-11-02 | Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant |
AT00974629T ATE287408T1 (de) | 1999-11-03 | 2000-11-02 | Tricyclische derivate der pyrazolcarbonsäure, ihre herstellung und sie enthaltende pharmazeutische zubereitungen |
US10/111,765 US6906080B1 (en) | 1999-11-03 | 2000-11-02 | Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same |
HU0203509A HUP0203509A3 (en) | 1999-11-03 | 2000-11-02 | Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same |
DE60017582T DE60017582T2 (de) | 1999-11-03 | 2000-11-02 | Tricyclische derivate der pyrazolcarbonsäure, ihre herstellung und sie enthaltende pharmazeutische zubereitungen |
AU12860/01A AU1286001A (en) | 1999-11-03 | 2000-11-02 | Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same |
US11/119,074 US7384960B2 (en) | 1999-11-03 | 2005-04-29 | Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9913846A FR2800375B1 (fr) | 1999-11-03 | 1999-11-03 | Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant |
FR99/13846 | 1999-11-03 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10111765 A-371-Of-International | 2000-11-02 | ||
US11/119,074 Division US7384960B2 (en) | 1999-11-03 | 2005-04-29 | Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001032663A2 true WO2001032663A2 (fr) | 2001-05-10 |
WO2001032663A3 WO2001032663A3 (fr) | 2001-09-27 |
Family
ID=9551735
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2000/003049 WO2001032663A2 (fr) | 1999-11-03 | 2000-11-02 | Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant |
Country Status (9)
Country | Link |
---|---|
US (2) | US6906080B1 (fr) |
EP (1) | EP1230244B1 (fr) |
JP (1) | JP4964380B2 (fr) |
AT (1) | ATE287408T1 (fr) |
AU (1) | AU1286001A (fr) |
DE (1) | DE60017582T2 (fr) |
FR (1) | FR2800375B1 (fr) |
HU (1) | HUP0203509A3 (fr) |
WO (1) | WO2001032663A2 (fr) |
Cited By (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003024935A2 (fr) * | 2001-09-19 | 2003-03-27 | Pharmacia Corporation | Composes de pyrazolyle substitues destines au traitement de l'inflammation |
WO2004098641A2 (fr) * | 2003-05-09 | 2004-11-18 | Pfizer Products Inc. | Composition pharmaceutique pour traiter l'obesite ou bien faciliter ou favoriser la perte de poids |
US6825209B2 (en) | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
US6900227B2 (en) | 2002-07-29 | 2005-05-31 | Hoffmann-La Roche Inc. | Benzodioxole derivatives |
WO2005108393A1 (fr) | 2004-05-10 | 2005-11-17 | F. Hoffmann-La Roche Ag | Amides pyrroles ou imidazoles destines au traitement de l'obesite |
EP1602658A1 (fr) * | 2004-05-24 | 2005-12-07 | Neuroscienze Oharmaness S.c.a.r.l. | Dérivés tricycliques de pyrazole comme antagonistes des récepteurs de cannabinoides |
EP1623741A2 (fr) | 2004-07-22 | 2006-02-08 | Cadila Healthcare Ltd. | LIGANDS DU RECEPTEUR CANNABINOIDE pour moduler LA POUSSE DES CHEVEUX |
FR2875230A1 (fr) * | 2004-09-13 | 2006-03-17 | Sanofi Aventis Sa | Derives de pyrazole condense, leur preparation et leur application en therapeutique |
WO2006025069A3 (fr) * | 2004-07-12 | 2006-04-27 | Cadila Healthcare Ltd | Nouveaux composes heterocycliques |
WO2006050842A1 (fr) | 2004-11-09 | 2006-05-18 | F. Hoffmann-La Roche Ag | Derives dibenzosuberone |
US7109216B2 (en) | 2001-09-21 | 2006-09-19 | Solvay Pharmaceuticals B.V. | 1H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
WO2006107561A1 (fr) * | 2005-03-31 | 2006-10-12 | Janssen Pharmaceutica, N.V. | Modulateurs cannabinoides a base de tetrahydrothiopyrano pyrazole |
US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US7135488B2 (en) | 2003-01-02 | 2006-11-14 | Hoffmann-La Roche Inc. | Pyrrolyl-thiazole derivatives |
US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7144890B2 (en) | 2004-01-28 | 2006-12-05 | Hoffman-La Roche Inc. | Spiro-pentacyclic compounds |
WO2006129178A1 (fr) * | 2005-06-02 | 2006-12-07 | Glenmark Pharmaceuticals S.A. | Nouveaux ligands des recepteurs des cannabinoides, compositions pharmaceutiques contenant ces ligands, et procede servant a leur preparation |
WO2007001939A1 (fr) * | 2005-06-27 | 2007-01-04 | Janssen Pharmaceutica N.V. | Composes tetrahydro-pyranopyrazole presentant des activites de modulation de cannabinoïde |
US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
WO2007038045A1 (fr) * | 2005-09-23 | 2007-04-05 | Janssen Pharmaceutica, N.V. | Modulateurs cannabinoïdes tétrahydro-indazolyle |
WO2007038036A1 (fr) * | 2005-09-23 | 2007-04-05 | Janssen Pharmaceutica, N.V. | Modulateurs cannabinoïdes de type hexahydrocycloheptapyrazole |
WO2007044215A1 (fr) * | 2005-09-23 | 2007-04-19 | Janssen Pharmaceutica, N.V. | Modulateurs du hexahydro-cyclooctyle pyrazole cannabinoïde |
US7229999B2 (en) | 2005-04-06 | 2007-06-12 | Hoffmann-La Roche Inc. | Pyridine-3-carboxamide derivatives as CB1 inverse agonists |
US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
US7294644B2 (en) | 2003-01-02 | 2007-11-13 | Hoffmann-La Roche Inc. | CB 1 receptor inverse agonists |
US7297707B2 (en) | 2003-06-20 | 2007-11-20 | Hoffmann-La Roche Inc. | Benzothiazolyl derivatives |
WO2008005489A2 (fr) | 2006-07-05 | 2008-01-10 | Aventis Agriculture | Composés dérivés de 1-aryl-5-alkylpyrazole, procédés de fabrication et procédés d'utilisation de ceux-ci |
US7329658B2 (en) | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
WO2008017381A1 (fr) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Imidazolidin-2,4-dione arylaminoaryl-alkyl-substituée, son procédé de fabrication, médicament contenant ce composé et son utilisation |
US7371751B2 (en) | 2003-12-08 | 2008-05-13 | Hoffmann-La Roche Inc. | Thiazole derivatives |
US7384945B2 (en) | 2004-10-27 | 2008-06-10 | Hoffmann-La Roche Inc. | Indole or benzimidazole derivatives as CB1 inverse agonists |
CN100432062C (zh) * | 2002-04-11 | 2008-11-12 | 赛诺菲-安万特 | 三联苯衍生物,它们的制备及包含它们的药物组合物 |
WO2009021740A2 (fr) | 2007-08-15 | 2009-02-19 | Sanofis-Aventis | Nouvelles tétrahydronaphtalines substituées, leurs procédés de préparation et leur utilisation comme médicaments |
US7629346B2 (en) | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
WO2010003624A2 (fr) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Composés hétérocycliques, leurs procédés de préparation, médicaments comprenant lesdits composés et leur utilisation |
WO2010068601A1 (fr) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant |
US7781593B2 (en) | 2006-09-14 | 2010-08-24 | Hoffmann-La Roche Inc. | 5-phenyl-nicotinamide derivatives |
ITMI20090262A1 (it) * | 2009-02-25 | 2010-08-26 | Neuroscienze Pharmaness S C Ar L | Composizioni farmaceutiche |
ITMI20090263A1 (it) * | 2009-02-25 | 2010-08-26 | Neuroscienze Pharmaness S C A R L | Composti farmaceutici |
US7825151B2 (en) | 2005-09-23 | 2010-11-02 | Janssen Pharmaceutica Nv | Hexahydro-cyclooctyl pyrazole cannabinoid modulators |
WO2011012674A1 (fr) | 2009-07-31 | 2011-02-03 | N.V. Organon | Dihydrobenzoindazoles |
WO2011023754A1 (fr) | 2009-08-26 | 2011-03-03 | Sanofi-Aventis | Nouveaux hydrates de fluoroglycoside hétéroaromatiques cristallins, substances pharmaceutiques comprenant ces composés et leur utilisation |
US7923465B2 (en) | 2005-06-02 | 2011-04-12 | Glenmark Pharmaceuticals S.A. | Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
WO2011157827A1 (fr) | 2010-06-18 | 2011-12-22 | Sanofi | Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases |
WO2012120058A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés d'oxathiazine substitués par des groupes benzyle ou hétérométhylène, leur procédé de production, leur utilisation comme médicament ainsi que produits pharmaceutiques les contenant et leur utilisation |
WO2012120052A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation |
WO2012120057A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation |
WO2012120053A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation |
WO2012120051A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés benzyl-oxathiazine substitués avec adamantane ou noradamantane, médicaments contenant ces composés et leur utilisation |
WO2012120055A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
WO2012120050A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, médicaments contenant ces composés et leur utilisation |
WO2012120054A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
WO2012120056A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
US8378096B2 (en) | 2005-09-23 | 2013-02-19 | Janssen Pharmaceutica N.V. | Hexahydro-cycloheptapyrazole cannabinoid modulators |
US8378117B2 (en) | 2005-09-23 | 2013-02-19 | Janssen Pharmaceutica N.V. | Hexahydro-cycloheptapyrazole cannabinoid modulators |
US8450357B2 (en) | 2008-11-19 | 2013-05-28 | Merial Limited | Compositions comprising an aryl pyrazole and/or a formamidine, methods and uses thereof |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20041032A1 (it) | 2004-05-24 | 2004-08-24 | Neuroscienze S C A R L | Compositi farmaceutici |
WO2006116183A1 (fr) * | 2005-04-25 | 2006-11-02 | Network Appliance, Inc. | Architecture de prise en charge de volumes epars |
US7840969B2 (en) * | 2006-04-28 | 2010-11-23 | Netapp, Inc. | System and method for management of jobs in a cluster environment |
US9173728B2 (en) | 2008-11-19 | 2015-11-03 | Merial Inc. | Multi-cavity container having offset indentures for dispensing fluids |
IT1395724B1 (it) | 2009-02-25 | 2012-10-19 | Neuroscienze Pharmaness S C A R L | Composti farmaceutici |
US8071587B2 (en) * | 2009-05-27 | 2011-12-06 | N. V. Organon | (Dihydro)imidazoiso[5,1-A]quinolines |
EP2499146B1 (fr) * | 2009-11-13 | 2016-09-21 | Merck Serono S.A. | Dérivés tricycliques d'amine de pyrazole |
US8410107B2 (en) | 2010-10-15 | 2013-04-02 | Hoffmann-La Roche Inc. | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides |
US8669254B2 (en) | 2010-12-15 | 2014-03-11 | Hoffman-La Roche Inc. | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents |
EP2789619A1 (fr) | 2013-04-12 | 2014-10-15 | Kemotech S.r.l. | Composés pharmaceutiques ayant une activité inhibitrice de l'angiogenèse |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3940418A (en) * | 1972-04-07 | 1976-02-24 | G. D. Searle & Co. | Esters and amides of 4,5-dihydrobenz[g]indazole-3-carboxylic acids and related compounds |
EP0477049A1 (fr) * | 1990-08-20 | 1992-03-25 | Sanofi | Dérivés d'amido-3 pyrazole, procédé pour leur préparation et compositions pharmaceutiques les contenant |
EP0568546A1 (fr) * | 1991-01-09 | 1993-11-10 | Glaxo Group Ltd | Derives cycliques pontes d'acetal. |
EP0576357A1 (fr) * | 1992-06-23 | 1993-12-29 | Sanofi | Dérivés du pyrazole, procédé pour leur préparation et compositions pharmaceutiques les contenant |
WO1996009304A1 (fr) * | 1994-09-20 | 1996-03-28 | G.D. Searle & Co. | Derives de benzopyranopyrazolyle pour le traitement des inflammations |
WO1997019063A1 (fr) * | 1995-11-23 | 1997-05-29 | Sanofi | Derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2714057B1 (fr) * | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
FR2800372B1 (fr) * | 1999-11-03 | 2001-12-07 | Sanofi Synthelabo | Derives tricycliques d'acide 1-benzylpyrazole-3- carboxylique, leur preparation, les medicaments en contenant |
-
1999
- 1999-11-03 FR FR9913846A patent/FR2800375B1/fr not_active Expired - Fee Related
-
2000
- 2000-11-02 EP EP00974629A patent/EP1230244B1/fr not_active Expired - Lifetime
- 2000-11-02 AU AU12860/01A patent/AU1286001A/en not_active Abandoned
- 2000-11-02 US US10/111,765 patent/US6906080B1/en not_active Expired - Lifetime
- 2000-11-02 WO PCT/FR2000/003049 patent/WO2001032663A2/fr active IP Right Grant
- 2000-11-02 AT AT00974629T patent/ATE287408T1/de not_active IP Right Cessation
- 2000-11-02 HU HU0203509A patent/HUP0203509A3/hu unknown
- 2000-11-02 DE DE60017582T patent/DE60017582T2/de not_active Expired - Lifetime
- 2000-11-02 JP JP2001535365A patent/JP4964380B2/ja not_active Expired - Fee Related
-
2005
- 2005-04-29 US US11/119,074 patent/US7384960B2/en not_active Expired - Lifetime
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3940418A (en) * | 1972-04-07 | 1976-02-24 | G. D. Searle & Co. | Esters and amides of 4,5-dihydrobenz[g]indazole-3-carboxylic acids and related compounds |
EP0477049A1 (fr) * | 1990-08-20 | 1992-03-25 | Sanofi | Dérivés d'amido-3 pyrazole, procédé pour leur préparation et compositions pharmaceutiques les contenant |
EP0568546A1 (fr) * | 1991-01-09 | 1993-11-10 | Glaxo Group Ltd | Derives cycliques pontes d'acetal. |
EP0576357A1 (fr) * | 1992-06-23 | 1993-12-29 | Sanofi | Dérivés du pyrazole, procédé pour leur préparation et compositions pharmaceutiques les contenant |
WO1996009304A1 (fr) * | 1994-09-20 | 1996-03-28 | G.D. Searle & Co. | Derives de benzopyranopyrazolyle pour le traitement des inflammations |
WO1997019063A1 (fr) * | 1995-11-23 | 1997-05-29 | Sanofi | Derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant |
Non-Patent Citations (2)
Title |
---|
FRAVOLINI, A. ET AL: "Synthesis and pharmacological activity of benzothiopyranopyrazole and benzothiopyranoisoxazole carboxamides" FARMACO, ED. SCI. (1978), 33(11), 855-65, XP002146285 * |
HAMILTON R W: "The antiarrhythmic and antiinflammatory activity of a series of tricyclic pyrazoles" JOURNAL OF HETEROCYCLIC CHEMISTRY,US,PROVO, UT, vol. 13, no. 3, 1 juin 1976 (1976-06-01), pages 545-553, XP002085959 ISSN: 0022-152X * |
Cited By (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6956052B2 (en) | 2001-09-19 | 2005-10-18 | Pharmacia Corporation | Substituted pyrazolyl compounds for the treatment of inflammation |
WO2003024935A3 (fr) * | 2001-09-19 | 2003-08-21 | Pharmacia Corp | Composes de pyrazolyle substitues destines au traitement de l'inflammation |
WO2003024935A2 (fr) * | 2001-09-19 | 2003-03-27 | Pharmacia Corporation | Composes de pyrazolyle substitues destines au traitement de l'inflammation |
US7109216B2 (en) | 2001-09-21 | 2006-09-19 | Solvay Pharmaceuticals B.V. | 1H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
CN100432062C (zh) * | 2002-04-11 | 2008-11-12 | 赛诺菲-安万特 | 三联苯衍生物,它们的制备及包含它们的药物组合物 |
US6825209B2 (en) | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
US6900227B2 (en) | 2002-07-29 | 2005-05-31 | Hoffmann-La Roche Inc. | Benzodioxole derivatives |
US7576088B2 (en) | 2002-07-29 | 2009-08-18 | Hoffman-La Roche Inc. | Benzodioxole derivatives |
US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
US7135488B2 (en) | 2003-01-02 | 2006-11-14 | Hoffmann-La Roche Inc. | Pyrrolyl-thiazole derivatives |
US7579369B2 (en) | 2003-01-02 | 2009-08-25 | Hoffmann-La Roche Inc. | CB 1 receptor inverse agonists |
US7294644B2 (en) | 2003-01-02 | 2007-11-13 | Hoffmann-La Roche Inc. | CB 1 receptor inverse agonists |
US7329658B2 (en) | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
US7354929B2 (en) | 2003-04-23 | 2008-04-08 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
WO2004098641A3 (fr) * | 2003-05-09 | 2005-01-20 | Pfizer Prod Inc | Composition pharmaceutique pour traiter l'obesite ou bien faciliter ou favoriser la perte de poids |
WO2004098641A2 (fr) * | 2003-05-09 | 2004-11-18 | Pfizer Products Inc. | Composition pharmaceutique pour traiter l'obesite ou bien faciliter ou favoriser la perte de poids |
US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
US7297707B2 (en) | 2003-06-20 | 2007-11-20 | Hoffmann-La Roche Inc. | Benzothiazolyl derivatives |
US7371751B2 (en) | 2003-12-08 | 2008-05-13 | Hoffmann-La Roche Inc. | Thiazole derivatives |
US7144890B2 (en) | 2004-01-28 | 2006-12-05 | Hoffman-La Roche Inc. | Spiro-pentacyclic compounds |
US7563910B2 (en) | 2004-05-10 | 2009-07-21 | Hoffmann-La Roche Inc. | Heterocyclic cannabinoid receptor antagonists |
WO2005108393A1 (fr) | 2004-05-10 | 2005-11-17 | F. Hoffmann-La Roche Ag | Amides pyrroles ou imidazoles destines au traitement de l'obesite |
EP1602658A1 (fr) * | 2004-05-24 | 2005-12-07 | Neuroscienze Oharmaness S.c.a.r.l. | Dérivés tricycliques de pyrazole comme antagonistes des récepteurs de cannabinoides |
US8106218B2 (en) | 2004-05-24 | 2012-01-31 | Neuroscienze Pharmaness S.C. A R.L. | Pharmaceutical compounds |
US7485730B2 (en) | 2004-05-24 | 2009-02-03 | Neuroscienze Pharmaness S.C. A R.L. | Pharmaceutical compounds |
EP2343302A1 (fr) | 2004-07-12 | 2011-07-13 | Cadila Healthcare Limited | Derives tricycliques de pyrazole comme modulateurs des recepteurs cannabinoides |
EA011307B1 (ru) * | 2004-07-12 | 2009-02-27 | Кадила Хелзкэр Лимитед | Трициклические производные пиразола в качестве модуляторов каннабиноидного рецептора |
US8030345B2 (en) | 2004-07-12 | 2011-10-04 | Cadila Healthcare Limited | Tricyclic pyrazole derivatives as cannabinoid receptor modulators |
WO2006025069A3 (fr) * | 2004-07-12 | 2006-04-27 | Cadila Healthcare Ltd | Nouveaux composes heterocycliques |
AP2228A (en) * | 2004-07-12 | 2011-04-01 | Cadila Healthcare Ltd | Tricyclic pyrazole derivatives as cannabinoid receptor modulators. |
EP1623741A2 (fr) | 2004-07-22 | 2006-02-08 | Cadila Healthcare Ltd. | LIGANDS DU RECEPTEUR CANNABINOIDE pour moduler LA POUSSE DES CHEVEUX |
WO2006030124A1 (fr) * | 2004-09-13 | 2006-03-23 | Sanofi-Aventis | Derives de pyrazole condense, leur preparation et leur application en therapeutique. |
FR2875230A1 (fr) * | 2004-09-13 | 2006-03-17 | Sanofi Aventis Sa | Derives de pyrazole condense, leur preparation et leur application en therapeutique |
US7384945B2 (en) | 2004-10-27 | 2008-06-10 | Hoffmann-La Roche Inc. | Indole or benzimidazole derivatives as CB1 inverse agonists |
US7786128B2 (en) | 2004-10-27 | 2010-08-31 | Hoffmann-La Roche Inc. | Indole or benzimidazole derivatives as CB1 inverse agonists |
WO2006050842A1 (fr) | 2004-11-09 | 2006-05-18 | F. Hoffmann-La Roche Ag | Derives dibenzosuberone |
US7220743B2 (en) | 2004-11-09 | 2007-05-22 | Hoffmann-La Roche Inc. | Heterocyclic CB1 receptor antagonists |
WO2006107561A1 (fr) * | 2005-03-31 | 2006-10-12 | Janssen Pharmaceutica, N.V. | Modulateurs cannabinoides a base de tetrahydrothiopyrano pyrazole |
US7524964B2 (en) | 2005-03-31 | 2009-04-28 | Janssen Pharmaceutica Nv | Tetrahydrothiopyrano pyrazole cannabinoid modulators |
US7229999B2 (en) | 2005-04-06 | 2007-06-12 | Hoffmann-La Roche Inc. | Pyridine-3-carboxamide derivatives as CB1 inverse agonists |
WO2006129178A1 (fr) * | 2005-06-02 | 2006-12-07 | Glenmark Pharmaceuticals S.A. | Nouveaux ligands des recepteurs des cannabinoides, compositions pharmaceutiques contenant ces ligands, et procede servant a leur preparation |
US7923465B2 (en) | 2005-06-02 | 2011-04-12 | Glenmark Pharmaceuticals S.A. | Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
WO2007001939A1 (fr) * | 2005-06-27 | 2007-01-04 | Janssen Pharmaceutica N.V. | Composes tetrahydro-pyranopyrazole presentant des activites de modulation de cannabinoïde |
US7825151B2 (en) | 2005-09-23 | 2010-11-02 | Janssen Pharmaceutica Nv | Hexahydro-cyclooctyl pyrazole cannabinoid modulators |
WO2007038045A1 (fr) * | 2005-09-23 | 2007-04-05 | Janssen Pharmaceutica, N.V. | Modulateurs cannabinoïdes tétrahydro-indazolyle |
CN101312725B (zh) * | 2005-09-23 | 2012-01-11 | 詹森药业有限公司 | 六氢-环辛四烯并吡唑大麻素调节剂 |
WO2007044215A1 (fr) * | 2005-09-23 | 2007-04-19 | Janssen Pharmaceutica, N.V. | Modulateurs du hexahydro-cyclooctyle pyrazole cannabinoïde |
WO2007038036A1 (fr) * | 2005-09-23 | 2007-04-05 | Janssen Pharmaceutica, N.V. | Modulateurs cannabinoïdes de type hexahydrocycloheptapyrazole |
US8378096B2 (en) | 2005-09-23 | 2013-02-19 | Janssen Pharmaceutica N.V. | Hexahydro-cycloheptapyrazole cannabinoid modulators |
US8378117B2 (en) | 2005-09-23 | 2013-02-19 | Janssen Pharmaceutica N.V. | Hexahydro-cycloheptapyrazole cannabinoid modulators |
US7851498B2 (en) | 2005-09-23 | 2010-12-14 | Janssen Pharmaceutica Nv | Hexahydro-cyclooctyl pyrazole cannabinoid modulators |
US7629346B2 (en) | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
US8785372B2 (en) | 2006-07-05 | 2014-07-22 | Aventis Agriculture | 1-aryl-5-alkyl pyrazole derivative compounds, processes of making and methods of using thereof |
US8445519B2 (en) | 2006-07-05 | 2013-05-21 | Aventis Agriculture | 1-aryl-5-alkyl pyrazole derivative compounds, processes of making and methods of using thereof |
WO2008005489A2 (fr) | 2006-07-05 | 2008-01-10 | Aventis Agriculture | Composés dérivés de 1-aryl-5-alkylpyrazole, procédés de fabrication et procédés d'utilisation de ceux-ci |
US7759381B2 (en) | 2006-07-05 | 2010-07-20 | Aventis Agriculture | 1-aryl-5-alkyl pyrazole derivative compounds, processes of making and methods of using thereof |
EP2465851A1 (fr) | 2006-07-05 | 2012-06-20 | Aventis Agriculture | Composés dérivés de 1-aryl-5-alkyl pyrazole, leurs procédés de fabrication et leurs procédés d'utilisation |
WO2008017381A1 (fr) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Imidazolidin-2,4-dione arylaminoaryl-alkyl-substituée, son procédé de fabrication, médicament contenant ce composé et son utilisation |
US7781593B2 (en) | 2006-09-14 | 2010-08-24 | Hoffmann-La Roche Inc. | 5-phenyl-nicotinamide derivatives |
WO2009021740A2 (fr) | 2007-08-15 | 2009-02-19 | Sanofis-Aventis | Nouvelles tétrahydronaphtalines substituées, leurs procédés de préparation et leur utilisation comme médicaments |
WO2010003624A2 (fr) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Composés hétérocycliques, leurs procédés de préparation, médicaments comprenant lesdits composés et leur utilisation |
US8450357B2 (en) | 2008-11-19 | 2013-05-28 | Merial Limited | Compositions comprising an aryl pyrazole and/or a formamidine, methods and uses thereof |
WO2010068601A1 (fr) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant |
EP2223914A1 (fr) | 2009-02-25 | 2010-09-01 | Neuroscienze Pharmaness S.C. A R.L. | Dérivés de pyrazole tricycliques condensés comme inhibiteurs de CB1 |
ITMI20090262A1 (it) * | 2009-02-25 | 2010-08-26 | Neuroscienze Pharmaness S C Ar L | Composizioni farmaceutiche |
ITMI20090263A1 (it) * | 2009-02-25 | 2010-08-26 | Neuroscienze Pharmaness S C A R L | Composti farmaceutici |
EP2223913A1 (fr) * | 2009-02-25 | 2010-09-01 | Neuroscienze Pharmaness S.C. A R.L. | Dérivés de pyrazole tricycliques et leurs microémulsions comme inhibiteurs de CB1 et/ou CB2 |
WO2011012674A1 (fr) | 2009-07-31 | 2011-02-03 | N.V. Organon | Dihydrobenzoindazoles |
WO2011023754A1 (fr) | 2009-08-26 | 2011-03-03 | Sanofi-Aventis | Nouveaux hydrates de fluoroglycoside hétéroaromatiques cristallins, substances pharmaceutiques comprenant ces composés et leur utilisation |
WO2011157827A1 (fr) | 2010-06-18 | 2011-12-22 | Sanofi | Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases |
WO2012120055A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
WO2012120050A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, médicaments contenant ces composés et leur utilisation |
WO2012120054A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
WO2012120056A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
WO2012120051A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés benzyl-oxathiazine substitués avec adamantane ou noradamantane, médicaments contenant ces composés et leur utilisation |
WO2012120053A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation |
WO2012120057A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation |
WO2012120052A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation |
WO2012120058A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés d'oxathiazine substitués par des groupes benzyle ou hétérométhylène, leur procédé de production, leur utilisation comme médicament ainsi que produits pharmaceutiques les contenant et leur utilisation |
Also Published As
Publication number | Publication date |
---|---|
DE60017582T2 (de) | 2006-03-23 |
US7384960B2 (en) | 2008-06-10 |
EP1230244B1 (fr) | 2005-01-19 |
US20050192332A1 (en) | 2005-09-01 |
EP1230244A2 (fr) | 2002-08-14 |
HUP0203509A2 (hu) | 2003-03-28 |
FR2800375A1 (fr) | 2001-05-04 |
JP2003513099A (ja) | 2003-04-08 |
HUP0203509A3 (en) | 2004-12-28 |
WO2001032663A3 (fr) | 2001-09-27 |
AU1286001A (en) | 2001-05-14 |
DE60017582D1 (de) | 2005-02-24 |
FR2800375B1 (fr) | 2004-07-23 |
JP4964380B2 (ja) | 2012-06-27 |
ATE287408T1 (de) | 2005-02-15 |
US6906080B1 (en) | 2005-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1230244B1 (fr) | Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant | |
EP0658546B1 (fr) | Dérivés de 3-pyrazolecarboxamide avec une affinité pour le récepteur des cannabinoides | |
EP1230222B1 (fr) | Derives tricycliques d'acides 1-benzylpyrazole-3-carboxylique comme antagonistes des recepteurs de cannabinoides | |
EP0876350B1 (fr) | Derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant | |
EP0656354B1 (fr) | N-pipéridino-3-pyrazolecarboxamide substitué | |
EP0576357B1 (fr) | Dérivés du pyrazole, procédé pour leur préparation et compositions pharmaceutiques les contenant | |
EP1150961B1 (fr) | Derives d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant | |
EP0868420B1 (fr) | Derives de 3-pyrazolecarboxamide avec une affinite pour le recepteur des cannabinoides | |
EP0477049B1 (fr) | Dérivés d'amido-3 pyrazole, procédé pour leur préparation et compositions pharmaceutiques les contenant | |
FR2789078A1 (fr) | Derives d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant | |
FR2713224A1 (fr) | N-pipéridino-3-pyrazolecarboxamide substitué. | |
MXPA01007781A (es) | Derivados de acido pirazolcarboxilico, su preparacion y composiciones farmaceuticas que los contienen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 535365 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000974629 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10111765 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2000974629 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000974629 Country of ref document: EP |